Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents01:20

Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents

721
Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
721
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

596
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
596
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

808
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
808
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

849
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
849
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents01:18

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

523
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
523
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

1.1K
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diterpenes from Helianthus annuus and their cytotoxicity in vitro.

Yao xue xue bao = Acta pharmaceutica Sinica·2007
Same author

Lignan oligosaccharide esters from Eritrichium rupestre.

Journal of natural products·2006
See all related articles

Related Experiment Video

Updated: Mar 17, 2026

Screening and Isolation of C-Glycoside-Cleaving Intestinal Bacteria
06:38

Screening and Isolation of C-Glycoside-Cleaving Intestinal Bacteria

Published on: February 28, 2025

764

Iridoid Glycosides from Tabebuia avellanedae.

Mao-Rong Suo1, Sheng-Ying Yan1

  • 1Jiyang College of Zhejiang Agriculture and Forestry University, Zhuji, 311800, P. R. China.

Chemistry & Biodiversity
|July 26, 2016
PubMed
Summary

Five new iridoid glycosides from Tabebuia avellanedae suppressed inflammatory cytokines and inhibited cytochrome CYP3A4 enzyme activity. These natural compounds show potential for anti-inflammatory applications.

Keywords:
Tabebuia avellanedaeAnti-inflammatory activitiesCYP3A4 EnzymeIridoids glycosidesTHP-1 Cell

More Related Videos

Evaluation of Antioxidant and Anthelmintic Properties of Tithonia diversifolia Extracts Against Gastrointestinal Nematode Eggs Using In Vitro Assays
05:19

Evaluation of Antioxidant and Anthelmintic Properties of Tithonia diversifolia Extracts Against Gastrointestinal Nematode Eggs Using In Vitro Assays

Published on: August 1, 2025

584
Author Spotlight: Exploring ShiDuGao's Multi-Target Approach in Anus Eczema Treatment
12:34

Author Spotlight: Exploring ShiDuGao's Multi-Target Approach in Anus Eczema Treatment

Published on: January 12, 2024

1.3K

Related Experiment Videos

Last Updated: Mar 17, 2026

Screening and Isolation of C-Glycoside-Cleaving Intestinal Bacteria
06:38

Screening and Isolation of C-Glycoside-Cleaving Intestinal Bacteria

Published on: February 28, 2025

764
Evaluation of Antioxidant and Anthelmintic Properties of Tithonia diversifolia Extracts Against Gastrointestinal Nematode Eggs Using In Vitro Assays
05:19

Evaluation of Antioxidant and Anthelmintic Properties of Tithonia diversifolia Extracts Against Gastrointestinal Nematode Eggs Using In Vitro Assays

Published on: August 1, 2025

584
Author Spotlight: Exploring ShiDuGao's Multi-Target Approach in Anus Eczema Treatment
12:34

Author Spotlight: Exploring ShiDuGao's Multi-Target Approach in Anus Eczema Treatment

Published on: January 12, 2024

1.3K

Area of Science:

  • Natural Product Chemistry
  • Pharmacology
  • Biochemistry

Background:

  • Tabebuia avellanedae is a plant source of bioactive compounds.
  • Iridoid glycosides are a class of natural products with diverse biological activities.
  • Inflammatory cytokines like TNF-α and IL-1β play key roles in inflammatory diseases.

Purpose of the Study:

  • To isolate and characterize novel iridoid glycosides from Tabebuia avellanedae.
  • To evaluate the anti-inflammatory potential of isolated compounds.
  • To investigate the effect of these compounds on cytochrome P450 enzyme activity.

Main Methods:

  • Isolation of compounds using H2O extract of Tabebuia avellanedae.
  • Structure elucidation using Nuclear Magnetic Resonance (NMR) and Mass Spectrometry (MS).
  • Assessment of inflammatory cytokine production in lipopolysaccharide (LPS)-stimulated human myeloma THP-1 cells.
  • Measurement of cytochrome CYP3A4 enzyme inhibition.

Main Results:

  • Five novel iridoid glycosides, avellanedaesides A-E (1-5), were successfully isolated and characterized.
  • The isolated compounds demonstrated suppression of tumor-necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) production.
  • Iridoid glycosides significantly inhibited the activity of the cytochrome CYP3A4 enzyme.

Conclusions:

  • Novel iridoid glycosides from Tabebuia avellanedae possess anti-inflammatory properties by reducing key inflammatory cytokines.
  • These compounds also exhibit inhibitory effects on cytochrome CYP3A4, suggesting potential drug-drug interaction implications.
  • Avellanedaesides A-E represent promising candidates for further investigation in the development of anti-inflammatory agents.